Inventor · disambiguated record
Mark Chiu
Also filed as: CHIU MARK · CHIU MARK L
13 granted patents·12 pending applications·99 citations·filing 2003–2024
90Inventor score
Files withJANSSEN BIOTECH INC14TAVOTEK BIOTHERAPEUTICS HONG KONG LTD5UNIV NEW YORK2ABBOTT LAB1GENMAB AS1
Top patents by PatentIndex Score
25 records- 0195US9593164B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2013·Granted Mar 14, 2017·34 cites·2 claims
- 0293US9580508B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2014·Granted Feb 28, 2017·19 cites·22 claims
- 0391US11149094B2Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutationsJANSSEN BIOTECH INC·Filed 2018·Granted Oct 19, 2021·9 cites·41 claims
- 0491US9644023B2Compositions and methods for phagocyte delivery of anti-staphylococcal agentsUNIV NEW YORK·Filed 2014·Granted May 9, 2017·19 cites·24 claims
- 0590US9695242B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2016·Granted Jul 4, 2017·8 cites·8 claims
- 0676US12247077B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2021·Granted Mar 11, 2025·0 cites·26 claims
- 0775US2020087407A1Bispecific EGFR/C-Met AntibodiesJANSSEN BIOTECH INC·Filed 2019·Application pending·0 cites
- 0870US6889727B2Apparatus and method for the preparation of experiments using proteins contained within gelsABBOTT LAB·Filed 2003·Granted May 10, 2005·9 cites·17 claims
- 0968US10865253B2Rodent bispecific heterodimeric proteinsGENMAB AS·Filed 2015·Granted Dec 15, 2020·1 cites·14 claims
- 1068US2018258173A1Bispecific EGFR/C-Met AntibodiesJANSSEN BIOTECH INC·Filed 2018·Application pending·0 cites
- 1168US2025215616A1Variable heavy chain only libraries, methods of preparation thereof, and uses thereofTAVOTEK BIOTHERAPEUTICS HONG KONG LTD·Filed 2024·Application pending·0 cites
- 1266US11359029B2FC engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using themJANSSEN BIOTECH INC·Filed 2020·Granted Jun 14, 2022·0 cites·13 claims
- 1361US2017275367A1Bispecific EGFR/C-Met AntibodiesJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 1459US12024796B2Variable heavy chain only libraries, methods of preparation thereof, and uses thereofTAVOTEK BIOTHERAPEUTICS HONG KONG LTD·Filed 2021·Granted Jul 2, 2024·0 cites·31 claims
- 1556US10087243B2Compositions and methods for phagocyte delivery of anti-staphylococcal agentsUNIV NEW YORK·Filed 2017·Granted Oct 2, 2018·0 cites·23 claims
- 1655US2025277051A1Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereofHANGZHOU UNOGEN BIOTECH LTD·Filed 2022·Application pending·0 cites
- 1755US2020010571A1Bispecific Anti-TNF-Alpha/IL-17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their UseJANSSEN BIOTECH INC·Filed 2019·Application pending·0 cites
- 1854US2025270314A1Anti-cdh17 monoclonal and bispecific antibodies and uses thereofTAVOTEK BIOTECH SUZHOU LTD·Filed 2022·Application pending·0 cites
- 1954US2025230248A1Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereofTAVOTEK BIOTHERAPEUTICS HONG KONG LTD·Filed 2022·Application pending·0 cites
- 2051US11078263B2Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising themJANSSEN BIOTECH INC·Filed 2018·Granted Aug 3, 2021·0 cites·13 claims
- 2151US10669344B2Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functionsJANSSEN BIOTECH INC·Filed 2017·Granted Jun 2, 2020·0 cites·20 claims
- 2248US2018044430A1FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using ThemJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 2347US2017218092A1Bispecific Anti-TNF-Alpha/IL17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their UseJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 2445US2022119549A1Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereofTAVOTEK BIOTHERAPEUTICS HONG KONG LTD·Filed 2021·Application pending·0 cites
- 2545US2022153869A1Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereofTAVOTEK BIOTHERAPEUTICS HONG KONG LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Chiu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →